Welcome
The Tara Miller Melanoma Center at the Abramson Cancer Center of the University of Pennsylvania is a comprehensive center that unites research, clinical care, education, and outreach programs to improve the lives of patients with melanoma. Despite tremendous advances in melanoma therapy, current therapies do not cure every patient. Many patients are still suffering and dying from melanoma. The Tara Miller Melanoma Center is dedicated to overcoming this challenge.
We are committed to providing exceptional care to all of our patients with melanoma and other types of skin cancers. Using a multidisciplinary approach, we deliver personalized care, integrating and connecting with providers from Dermatology, Medical Oncology, Surgical Oncology, Radiation Oncology, and Pathology. We also collaborate with basic, translational, and population scientists who study new ways to prevent, diagnose, and treat melanoma. The Center supports innovative research to truly change the trajectory of the disease for an individual patient. The Tara Miller Melanoma Center is a place where patients and their families can turn to for education and find up to date information regarding the best treatments for melanoma.
The Tara Miller Melanoma Center was established in 2019 with generous support from Debbie and George Miller in honor of their daughter, Tara Miller. As Dr. Bob Vonderheide, the Director of the Abramson Cancer Center said, “The number of people who were moved by Tara’s courage and her character is second only the number of lives that will be forever changed by her legacy”.
Drs. John Miura and J. Nick Lukens receive the ACC Carole P. & F. Otto Haas Junior Faculty Award in Clinical Oncology! This award provides start-up support and salary funds to a junior faculty member pursuing a career in clinical oncology.
Dr. Miura is an exceptional surgical oncologist in the Division of Endocrine and Oncologic Surgery and is a member of the Tara Miller Melanoma Center. He is also actively involved in melanoma and skin cancer research, including the rare tumor type Merkel cell carcinoma. Currently, Dr. Miura has an open phase 2 clinical trial which administers neo-adjuvant pembrolizumab for patients with resectable Merkel cell carcinoma.
Dr. Lukens is s a phenomenal radiation oncologist within the Department of Radiation Oncology. He is the Chief of the Head & Neck Service in Radiation Oncology and is a member of the Tara Miller Melanoma Center. Additionally, Dr. Lukens is engaged in melanoma and skin cancer research, particularly focusing on the integration of immunotherapy and radiotherapy for patients with metastatic melanoma.